Tepoxalin (Zubrin®) a novel dual cyclooxygenase/5-lipoxygenase-inhibitor for dogs;Tepoxalin (Zubrin®) ein neuer dualer Zyklooxygenase/5-Lipoxygenasehemmer für Hunde

Praktische Tierarzt

Volumn 82, Issue 12, 2001, Pages 1014-1021

  Goossens, L ^a,b   Berthomme I ^a,b  

^a Wissenschaftlichen Abt Fa Essex T   (Germany)

^b Essex Tierarznei   (Germany)

Author keywords

Dog; Musculoskeletal system; Osteoarthritis; Tepoxalin

Indexed keywords

EID: 0346348026     PISSN: 0032681X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. ARGENTIERI, D. C. et al.: Topical and in vitro pharmacology of tepoxalin: A new dual cyclooxygenase (CO)/lipoxygenase (LO) inhibitor. FASEB J. 2, A369 (1988).
2. ARGENTIERI, D. C., D. W. ANDERSON, D. M. RITCHIE, M. E. ROSENTHALE und R. J. CAPETOLA: Tepoxalin (RWJ 20485) inhibits prostaglandin (PG) and leukotriene (LT) production in adjuvant arthritic rats and in dog knee joints challenged with sodium urate and immune complexes. FASEB J. 4, A1122 (1990).
3. ARGENTIERI, D. C. et al.: Tepoxalin: a dual cyclooxygenase/5-Lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J. Pharmacol. Exp. Ther., 271, 1399-1408 (1994).
4. CAPETOLA, R. J. et al.: Pulmonary and anti-inflammatory profile of tepoxalin, a dual cyclooxygenase (CO)/lipoxygenase (LO) inhibitor. FASEB J. 2, A369 (1988).
5. BLACKWELL, G. J. und R. J. FLOWER: 1-Phenyl-3 pyrazolidone: An inhibitor of arachidonate oxidation in lung and platelets. Br. J. Pharmacol. 63, 360 (1978).
6. FIEBICH, B. L., T. J. HOFER, K. LIEB, M. HUELL, R. D. BUTCHER, G. SCHUMANN, K. SCHULZEOSTHOFF und J. BAUER: The non-steroidal antiinflammatory drug tepoxalin inhibits interleukin-6 and alpha1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IκB-alpha. Neuropharmacology, 38, 1325-1333 (1999).
7. FORD-HUTCHINSON, A. W.: Leukotriene B4 in inflammation. Crit. Rev. Immunol. 10, 1-12 (1990).
8. FRÖLICH, J. C.: Review: a classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends pharmacol. Sci. 18, 30-34 (1997).
9. FUNG-LEUNG, W.-P., B. L. POPE, E. CHOURMOUZIS, J. A. PANAKOS und C. Y. LAU: Tepoxalin, a novel immunomodulatory compound, synergizes with CSA in suppression of graftversus-host reaction and allogeneic skin graft rejection. Transplantation 60, 362-368 (1995).
10. HULSE, D.: Treatment methods for pain in the osteoarthritic patient. Clin. Pharmcol. Ther. 28, 361-375 (1998).
11. KAZMI, S. M. I., R. K. PLANTE, V. VISCONTI, G. R. TAYLOR, L. ZHOU und C. Y. LAU: Suppression of NFκB activation and NF κB-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J. Cell Biochem., 57, 299-310 (1995).
12. KIRCHNER, T., B. APARICIO, D. C. ARGENTIERI, C. Y. LAU und D. M. RITCHIE: Effects of tepoxalin, a dualinhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot, Essent Fatty Acids, 56, 417-423 (1997).
13. KNIGHT, E. V., J. P. KIMBALL, C. M. KEENAN, I. L. SMITH, F. A. WONG, D. S. BARRETT, A. M. DEMPSTER, W. G. LIEUALLEN, D. PANIGRAHI, W. J. POERS und R. J. SZOT: Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase und 5-Lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam. Appl. Toxicol. 33, 38-48 (1996).
14. LEES, P. und A. J. HIGGINS: Clinical pharmacology and therapeutic uses of nonsteroidal antiinflammatory drugs in the horse. Equine Vet. J. 17, 83-96 (1985).
15. LEWIS, R. A., K. F. AUSTEN und R. J. SOBERMAN: Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation of pathobiology in human diseases. N. Engl. J. Med. 323, 645 (1990).
16. MORALES, R. E., B. R. JOHNSON und S. SZABO: Endothelin induces vascular and mucosal lesions, enhances the injury by HCl/ethanol, and the antibody exerts gastroprotection. FASEB J., 6, 2354 (1992).
17. RITCHIE, D. M., D. C. ARGENTIERI, C. LAU und A. G. BARBONE: Cytokine modulation by tepoxalin-a dual cyclooxygenase (CO)/lipoxygenase (LO) inhibitor with potential antirheumatic activity. Abstract book world congress inflammation, Wien (1993).
18. RITCHIE, D. M., D. C. ARGENTIERI, B. L. APARICIO, R. K. PLANTE, C. Y. LAU und A. G. BARBONE: Cytokine modulation by tepoxalin, a new potential antirheumatic. Int. J. Immunopharmac., 17, 805-812 (1995).
19. SMITH, W. L. und D. L. DeWITT: Differential interactions of prostaglandin endoperoxide synthases with nonsteroidal anit-inflammatory drugs. Curr. Opin. Invest. Drugs 3, 1-11 (1994).
20. VANE, J. R.: Towards a better aspirin. Nature 367, 215-216 (1994).
21. VAUGHAN-SCOTT, T. und J. H. TAYLOR.: The pathophysiology and medical management of canine osteoarthritis. JI S. Afr. vet. Ass. 68, 21-25 (1997).
22. WALDMANN, S. A., C. VITOW, B. OSBORNE, L. GILLEN, D. C. ARGENTIERI, F. A. WONG, I. L. SMITH, A. CHOW, J. MISITI und T. D. BJORNSONN: Pharmacokinetics and pharmacodynamics of Tepoxalin after single oral dose administration to healthy volunteers. J. Clin. Pharmacol., 36, 462-468 (1996).
23. WALLACE, J. L., D.-M. McCAFFERTY, L. CARTER, W. McKNIGHT und D. ARGENTIERI.: Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxlin: anti-inflammatory without gastropathy? Gastroenterology, 105, 1630-1636 (1993).
24. WILLBURGER, R. E., R. H. WITTENBERG, K. SCHMIDT, K. S. KLEEMEYER und B. A. PESKAR: Antiinflammatory effect of tepoxalin: blood and synovial tissue studied in patients with knee arthrosis. Acta Orthop. Scand. 69, 295-300 (1998).
25. ZHOU, L, B. L. POPE, E. ChOURMOUZIS, W.-P. FUNG-LEUNG und C. Y. LAU: Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression. Eur. J. Immunol. 26, 120-129 (1996).
26. ZHOU, L, D. M. RITCHIE, E. Y. WANG, A. G. BARBONE, D. ARGENTIERI und C. Y. LAU. Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A. J. Immunol.: 5026-5037 (1994).